Spyre Therapeutics (SYRE) Stock

NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

WALTHAM, Mass. , Dec. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 45,000 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").

Spyre is concurrently advancing two anti-TL1A molecules into first-in-human studies Preclinical data for both SPY002 molecules demonstrate picomolar potency and potential for quarterly or twice-yearly dosing, suggesting opportunity for improved efficacy and convenience over first-generation anti-TL1As which are dosed every two to four weeks Interim pharmacokinetic, pharmacodynamic, and safety data from healthy volunteers for both SPY002 molecules anticipated in the second quarter of 2025 Spyre expects to introduce SPY002 to its planned Phase 2 study in ulcerative colitis exploring quarterly monotherapies and combinations; the Company also intends to initiate a proof-of-concept Phase 2 study outside of IBD in 2025 Strong balance sheet with proforma cash, cash equivalents, and marketable securities balance on September 30, 2024 of over $630M following recent oversubscribed $230M financing, providing cash runway into the second half of 2028 WALTHAM, Mass. , Dec. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that it has initiated dosing of healthy volunteers in Phase 1 clinical trials of two investigational half-life extended anti-TL1A monoclonal antibodies.

NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASDAQ:SYRE). Investors who purchased Spyre securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRE.

NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASDAQ:SYRE). Investors who purchased Spyre securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRE.

NEW YORK, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASDAQ:SYRE). Investors who purchased Spyre securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRE.

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASDAQ:SYRE). Investors who purchased Spyre securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRE.

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK , Nov. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.